Latest News
SEARCH
NEWARK,U.S.A.andNANJING,China—BiosionUSA,Inc.(Biosion),aglobalR&Dbiotechnologycompany,todayannouncedtheupcomingpresentationofdiscoveryanddevelopmentdataforBSI-038,ananti-CD40agonisticantibodyatt...2023-05-08
NEWARK,U.S.A.andNANJING,China.April4,2023–BiosionUSA,Inc.(Biosion),aglobalclinical-stageR&Dbiotechnologycompany,todayannouncedthatithassuccessfullyopenedanINDfollowingreviewbytheU.S.FoodandDrugA...2023-04-04
NEWARK,U.S.A.andNANJING,China，BiosionUSA,Inc.(Biosion),aglobalR&Dbiotechnologycompany,todayannouncedtheupcomingpresentationsofnon-clinicaldatafromitsoncologypipeline,includingBSI-507:anti-PD1ⅹanti-PVR...2023-03-20
- Biosion Presents Discovery and Development Data at PEGS for its Anti-CD40 Agonistic AntibodyNEWARK,U.S.A.andNANJING,China—BiosionUSA,Inc.(Biosion),aglobalR&Dbiotechnologycompany,todayannouncedtheupcomingpresentationofdiscoveryanddevelopmentdataforBSI-038,ananti-CD40agonisticantibodyatt...2023-05-08
- Biosion Initiates Phase II Clinical Trial of BSI-045B in Atopic DermatitisNEWARK,U.S.A.andNANJING,China.April4,2023–BiosionUSA,Inc.(Biosion),aglobalclinical-stageR&Dbiotechnologycompany,todayannouncedthatithassuccessfullyopenedanINDfollowingreviewbytheU.S.FoodandDrugA...2023-04-04
- Biosion bispecific antibody therapies to be featured at the American Association for Cancer Research (AACR) annual meeting 2023NEWARK,U.S.A.andNANJING,China，BiosionUSA,Inc.(Biosion),aglobalR&Dbiotechnologycompany,todayannouncedtheupcomingpresentationsofnon-clinicaldatafromitsoncologypipeline,includingBSI-507:anti-PD1ⅹanti-PVR...2023-03-20
- Biosion Announces Research Collaboration with ImmunoGen to Create Novel Antibody-Drug ConjugatesCollaborationtoexplorepotentialofcreatingnext-generationantibody-drugconjugateswithBiosion’sSynTracer®internalizationplatformandImmunoGen’sproprietarylinker-payloadtechnologyNEWARK,Del...2022-12-13
- Anti-Siglec-15 Monoclonal Receives FDA Clearance of IND ApplicationNEWARK,Delaware,U.S.A.andNANJING,China,December2,2022——Biosion’spartner,PyxisOncology(NASDAQ:PYXS)announcedthatithasreceivedclearanceforitsInvestigationalNewDrug(IND)applicationfromt...2022-12-03
- Biosion, Inc. Appoints Dr. Rakesh Dixit, ADC Thought Leader, to Advisory BoardNEWARK, Delaware, U.S.A. and NANJING, China, September 7, 2022 - Biosion, Inc. ("Biosion"), a global R&D biotechnology company, today announced the appointment of Rakesh Dixit, Ph.D., DABT to its...2022-09-07
- 1
- 2
- 3
Biosion’s Mission
To discover and develop innovative biologics through the synergy of great science, cutting edge technologies and superior craftsmanship for patients worldwide
FOLLOW US
Copyright © 2022. Biosion All rights reserved. 苏ICP备2022027163号
Biosion USA, Inc. 1 Innovation Way, Suite 300, Newark, Delaware 19711, USA
BD@Biosion.com
1-302-998-5126
Latest News
SEARCH
- Biosion Presents Discovery and Development Data at PEGS for its Anti-CD40 Agonistic Antibody2023-05-08
- Biosion Initiates Phase II Clinical Trial of BSI-045B in Atopic Dermatitis2023-04-04
- Biosion bispecific antibody therapies to be featured at the American Association for Cancer Research (AACR) annual meeting 20232023-03-20
- Biosion Presents Discovery and Development Data at PEGS for its Anti-CD40 Agonistic AntibodyNEWARK,U.S.A.andNANJING,China—BiosionUSA,Inc.(Biosion),aglobalR&Dbiotechnologycompany,todayannouncedtheupcomingpresentationofdiscoveryanddevelopmentdataforBSI-038,ananti-CD40agonisticantibodyatt...2023-05-08
- Biosion Initiates Phase II Clinical Trial of BSI-045B in Atopic DermatitisNEWARK,U.S.A.andNANJING,China.April4,2023–BiosionUSA,Inc.(Biosion),aglobalclinical-stageR&Dbiotechnologycompany,todayannouncedthatithassuccessfullyopenedanINDfollowingreviewbytheU.S.FoodandDrugA...2023-04-04
- Biosion bispecific antibody therapies to be featured at the American Association for Cancer Research (AACR) annual meeting 2023NEWARK,U.S.A.andNANJING,China，BiosionUSA,Inc.(Biosion),aglobalR&Dbiotechnologycompany,todayannouncedtheupcomingpresentationsofnon-clinicaldatafromitsoncologypipeline,includingBSI-507:anti-PD1ⅹanti-PVR...2023-03-20
- Biosion Announces Research Collaboration with ImmunoGen to Create Novel Antibody-Drug ConjugatesCollaborationtoexplorepotentialofcreatingnext-generationantibody-drugconjugateswithBiosion’sSynTracer®internalizationplatformandImmunoGen’sproprietarylinker-payloadtechnologyNEWARK,Del...2022-12-13
- Anti-Siglec-15 Monoclonal Receives FDA Clearance of IND ApplicationNEWARK,Delaware,U.S.A.andNANJING,China,December2,2022——Biosion’spartner,PyxisOncology(NASDAQ:PYXS)announcedthatithasreceivedclearanceforitsInvestigationalNewDrug(IND)applicationfromt...2022-12-03
- Biosion, Inc. Appoints Dr. Rakesh Dixit, ADC Thought Leader, to Advisory BoardNEWARK, Delaware, U.S.A. and NANJING, China, September 7, 2022 - Biosion, Inc. ("Biosion"), a global R&D biotechnology company, today announced the appointment of Rakesh Dixit, Ph.D., DABT to its...2022-09-07
- 1
- 2
- 3
Biosion’s Mission
To discover and develop innovative biologics through the synergy of great science, cutting edge technologies and superior craftsmanship for patients worldwide
FOLLOW US
Copyright © 2022. Biosion All rights reserved. 苏ICP备2022027163号
Biosion USA, Inc. 1 Innovation Way, Suite 300, Newark, Delaware 19711, USA
BD@Biosion.com
1-302-998-5126